# Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease

> **NCT00169923** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Leiden University Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Kidney Disease
- Inflammation

## Interventions

- **DRUG:** rosiglitazone

## Key facts

- **NCT ID:** NCT00169923
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2009-05
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** it was not possible to recruit any patient in the study
- **Last updated:** 2008-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00169923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00169923, "Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00169923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*